GAIN Trial top-line data for disease modification in Alzheimer’s expected by mid-November 2021
Phase 2 REPAIR sub-study results evaluating periodontal disease expected by mid-November 2021
Current cash position sufficient to fund operations through 2023
https://finance.yahoo.com/news/cortexyme-provides-business-reports-second-120000774.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.